Abeona Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Abeona Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Abeona Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Abeona Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for severe, life-threatening conditions. Its pipeline includes programs for recessive dystrophic epidermolysis bullosa (RDEB) and several inherited eye diseases using adeno-associated virus (AAV) gene therapy approaches.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Abeona’s R&D is focused on advancing and commercializing cell and gene therapy programs, including the development of ZEVASKYN and ABO-504. The company is leveraging its expertise in research and development to introduce efficacious and safe therapeutics aimed at transforming the standard of care in devastating diseases. The company is also actively seeking U.S. and international patent protection for various technologies, including AAV capsids and AAV-based biological products, and is involved in strategic partnerships and collaborations with academic institutions and industry partners to accelerate research and development. Its R&D unit is responsible for developing cell and gene therapy programs, including the design and implementation of novel AAV vector strategies, conducting preclinical and clinical studies, and ensuring compliance with regulatory requirements. The unit also focuses on securing intellectual property rights and collaborating with external partners to enhance research and development efforts. In FY2025, the company spent US$26.8 million on its R&D activities, which grew 21.9% YoY.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer